Download PDF
TumorDiagnostik & Therapie 2012; 33(3): 154-161
DOI: 10.1055/s-0031-1299450
Übersichtsartikel (Review)
© Georg Thieme Verlag KG Stuttgart · New York

Nebenwirkungsmanagement von Afatinib

How to Address the Side Effects of Afatinib
L. Zimmer
1   Klinik f. Dermatologie und Venerologie, Universitätsklinikum Essen
,
E. Livingstone
1   Klinik f. Dermatologie und Venerologie, Universitätsklinikum Essen
,
J. Rüffer
2   Deutsche Fatigue Gesellschaft e. V.
,
K. Jordan
3   Klinik u. Poliklinik für Innere Medizin IV, Universitätsklinikum Halle
› Author Affiliations
Further Information

Publication History

Publication Date:
23 April 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die neuen, oral verabreichten Zytostatika vom Typ der Tyrosinkinasehemmstoffe (TKI) z. B. gegen den Wachstumsfaktor-Rezeptor EGFR/HER2 (Epidermal growth factor receptor) sind mit typischen Nebenwirkungen wie Hautveränderungen und Diarrhöen assoziiert. Auch wenn diese klinisch meist mild und nicht vital gefährdend sind, kann die psychische Belastung für den Patienten erheblich sein und bis zum Therapieabbruch führen. Durch die einfache orale Administration kommen EGFR-TKI aus den Fachkliniken zunehmend in den Bereich der niedergelassenen Ärzte. Daher soll dieser Review dem niedergelassenen Arzt konkrete Handlungsanweisungen zur Bewertung und Therapie der häufigsten Nebenwirkungen an die Hand geben. Mittlerweile sind mehrere TKI zugelassen, weitere, wie beispielsweise Afatinib, befinden sich in späten Stadien der klinischen Prüfung. Afatinib ist eine Substanz der neuesten Generation (irreversible TKI) mit breiterem TKI-Spektrum (Erb familyblocker) und den klassentypischen Nebenwirkungen.

Gastrointestinale Nebenwirkungen wie Durchfall sind insbesondere zu Behandlungsbeginn häufig, können aber analog zu Chemotherapeutika nach dem hier vorgestellten Schema auf Basis von Loperamid und ggf. Octreotid behandelt werden. Stomatitis/Mukositis können durch gezielte Pflege und Kühlung gelindert werden. Für akneiforme Dermatitiden ist in Abhängigkeit vom Schweregrad eine gezielte topische oder systemische Antibiose in Verbindung mit weiteren lokalen Maßnahmen sinnvoll. Fatigue ist bei Afatinib eine eher seltener auftretende, dennoch ernst zu nehmende Nebenwirkung.

Abstract

Tyrosine kinase inhibitors (TKI) of growth factor receptors such as EGFR/HER2, a new generation of anti-tumor drugs, are usually associated with typical side effects such as cutaneous and gastrointestinal adverse events. Even if those side effects are mild and not clinically threatening in most cases, the psychological burden may weigh heavy on the affected patients and can even result in treatment termination. Due to their simple mode of administration, EGFR-TKI are being used increasingly in outpatient settings. This review presents specific assessment and handling guidelines for the most frequent side effects. By this point of time, several EGFR-TKI have been approved, and further drugs e. g. afatinib are in late stages of clinical trials. Afatinib is a member of the most recent generation of TKIs (irreversible TKIs) with a broader field of action (Erb family blocker) and the typical class side effects.

Gastrointestinal side effects such as diarrhea are frequent and occur in most cases during the first days of treatment. Management of diarrhea is recommended to be handled similar to chemotherapy-induced diarrhea based on loperamide and octreotide as presented in this review. Relief for stomatitis/mucositis can be provided with effective topical care and cooling. Rash and dermatitis warrant specific topical and/or oral antibiotics in combination with local care, depending on the severity. Fatigue is infrequent under afatinib, but, if present, should be taken seriously.

Schlüsselwörter

TKI - EGFR - Sicherheit - Verträglichkeit - Nebenwirkungen - Hautveränderungen - Durchfall

Key words

TKI - EGFR - safety - tolerability - side effects - cutaneous toxicity - diarrhea
 

  • Literatur

  • 1 Gusterson B, Cowley G, Smith JA et al. Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 1984; 8: 649-658
    CrossrefPubMedGoogle Scholar
  • 2 Binder D, Buckendahl AC, Hübner RH et al. Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker. Med Oncol 2010; Epub ahead of print. DOI: 10.1007/s12032-010-9767-x.
    PubMedGoogle Scholar
  • 3 Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?. Oncology 2003; 11 (Suppl. 12) 23-28
    PubMedGoogle Scholar
  • 4 Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non – small-cell lung cancer. J Clin Oncol 2004; 22 (16) 3238-3247
    CrossrefPubMedGoogle Scholar
  • 5 Agero AL, Dusza SW, Benvenuto-Andrade C et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55 (04) 657-670
    CrossrefPubMedGoogle Scholar
  • 6 Peeters M, Siena S, Van Cutsem E et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumabmonotherapy. Cancer 2009; 115 (07) 1544-1554
    CrossrefPubMedGoogle Scholar
  • 7 Daten nicht publiziert, on File Boehringer Ingelheim Pharma GmbH & Co. KG, Deutschland.
    PubMedGoogle Scholar
  • 8 Miller VA, Hirsh V, Cadranel J et al. Phase IIb/III double-blind randomized trial of afatinib (BIBW2992, an irreversibleinhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1) LBA 1. Ann Oncol 2010; 21 (Suppl. 08) VIII1-VIII12 DOI: 10.1093/annonc/mdq601.
    PubMedGoogle Scholar
  • 9 Deininger MW, O’Brien SG, Ford JM et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21 (08) 1637-1647
    CrossrefPubMedGoogle Scholar
  • 10 http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_v40
    PubMed
  • 11 Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010; 2: 51-63
    CrossrefPubMedGoogle Scholar
  • 12 Benson 3rd AB, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22 (14) 2918-2926
    CrossrefPubMedGoogle Scholar
  • 13 Bowen JM, Stringer AM, Gibson RJ et al. Probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007; 6 (09) 1449-1454
    CrossrefPubMedGoogle Scholar
  • 14 Pytlík R, Benes P, Patorková M et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo-controlled study. Bone Marrow Transplant 2002; 30 (12) 953-961
    CrossrefPubMedGoogle Scholar
  • 15 Reardon DA, Quinn JA, Vredenburgh J et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005; 103 (02) 329-338
    CrossrefPubMedGoogle Scholar
  • 16 Cascinu S, Fedeli A, Fedeli SL et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11 (01) 148-151
    PubMedGoogle Scholar
  • 17 Zidan J, Haim N, Beny A et al. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 2001; 12 (02) 227-229
    CrossrefPubMedGoogle Scholar
  • 18 Rubenstein EB, Peterson DE et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100 (Suppl. 09) 2026-2046
    CrossrefPubMedGoogle Scholar
  • 19 Sonis ST. A biological approach to mucositis. J Support Oncol 2004; 2 (01) 21-32
    PubMedGoogle Scholar
  • 20 Epstein JB, Klasser GD. Emerging approaches for prophylaxis and management of oropharyngealmucositis in cancer therapy. Expert Opin Emerg Drugs 2006; 11 (02) 353-373
    CrossrefPubMedGoogle Scholar
  • 21 Wollenberg A, Kroth J, Hauschild A et al. Hautreaktionen unter EGFR-Inhibitoren-Klinik und Management. Dtsch Med Wochenschr 2010; 135 (04) 149-154
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Jost M, Kari C, Rodeck U. The EGF receptor – an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10 (07) 505-510
    PubMedGoogle Scholar
  • 23 Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4 (02) 107-119
    CrossrefPubMedGoogle Scholar
  • 24 Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6 (10) 803-812
    CrossrefPubMedGoogle Scholar
  • 25 Potthoff K, Hofheinz R, Hassel JC et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22 (03) 524-535
    CrossrefPubMedGoogle Scholar
  • 26 Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6 (07) 491-500
    CrossrefPubMedGoogle Scholar
  • 27 Balagula Y, Garbe C, Myskowski PL et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011; 50 (02) 129-146
    CrossrefPubMedGoogle Scholar
  • 28 Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22 (15) 3003-3015
    CrossrefPubMedGoogle Scholar
  • 29 Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12 (07) 2166-2171
    CrossrefPubMedGoogle Scholar
  • 30 Hughes AN, O’Brien ME, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27 (08) 1220-1226
    CrossrefPubMedGoogle Scholar
  • 31 Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144 (06) 1169-1176
    CrossrefPubMedGoogle Scholar
  • 32 Bernier J, Bonner J, Vermorken JB et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19 (01) 142-149
    PubMedGoogle Scholar
  • 33 Mitra SS, Simcock R. Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 2006; 24: 28-29
    CrossrefPubMedGoogle Scholar
  • 34 Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19 (13) 3267-3279
    PubMedGoogle Scholar
  • 35 Melosky B, Burkes R, Rayson D et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16 (01) 16-26
    PubMedGoogle Scholar
  • 36 Wollenberg A, Moosmann N, Klein E et al. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008; 17: 790-792
    CrossrefPubMedGoogle Scholar
  • 37 Scope A, Agero AL, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25 (34) 5390-5396
    CrossrefPubMedGoogle Scholar
  • 38 Jatoi A, Rowland K, Sloan JA et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113 (04) 847-853
    CrossrefPubMedGoogle Scholar
  • 39 Lacouture ME, Mitchell EP, Piperdi B et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28 (08) 1351-1357
    CrossrefPubMedGoogle Scholar
  • 40 Perez-Soler R, Zou Y et al. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J Clin Oncol 2006; 24 (Suppl. 18) 3036a
    PubMedGoogle Scholar
  • 41 Joshi SS, Ortiz S, Witherspoon JN et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010; 116 (16) 3916-3923
    CrossrefPubMedGoogle Scholar
  • 42 Traeger L, Braun IM, Greer JA et al. Parsing Depression From Fatigue in Patients with Cancer Using the Fatigue Symptom Inventory. J Pain Symptom Manage 11.03.2011; [Epub ahead of print]
    PubMedGoogle Scholar
  • 43 Breitbart W, Alici Y. Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. Clin J Oncol Nurs 2008; 12 (Suppl. 05) 27-36
    CrossrefPubMedGoogle Scholar
  • 44 Mustian KM, Morrow GR, Carroll JK et al. Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist 2007; 12 (Suppl. 01) 52-67
    CrossrefPubMedGoogle Scholar